Article
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Oncotarget - 6 Oct 2015
Menke-van der Houven van Oordt Catharina Willemien, Gootjes Elske C, Huisman Marc C, Vugts Danielle J, Roth Chantal, Luik Anne Marije, Mulder Emma R, Schuit Robert C, Boellaard Ronald, Hoekstra Otto S, van Dongen Guus Ams, Verheul Henk M W
Abstract excerpt
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for clinical benefit of anti-EGFR treatment, biodistribution and tumor uptake of (89)Zr-cetuximab by Positron Emission...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.